Recent moves of note in and around the biotech and pharma industries.
Turning Point Therapeutics has announced the appointment of Siegfried Reich (photo) as executive vice president and CSO. Reich has over 25 years of pharma and biotech experience developing more than 20 drug candidates. He was most recently senior vice president of research and cofounder of eFFECTOR Therapeutics, and before that was vice president and head of drug discovery at SGX, vice president and head of viral and ophthalmic diseases at Pfizer, and director and head of medicinal chemistry at Agouron.
“With a strong commitment to build on the four internally discovered drug candidates in our pipeline, we wanted to attract a proven leader and visionary CSO to advance our research strategy,” said Athena Countouriotis, president and CEO of Turning Point. “Siegfried is an ideal fit for our team, with deep discovery and novel-target-identification expertise, and a proven track record of developing drug candidates for difficult-to-drug targets through disciplined discovery and medicinal, structure- and fragment-based chemistry.”
Robert Abraham has been named CSO of Vividion Therapeutics. He joins the company from Pfizer, where he most recently served as senior vice president and group head, oncology R&D.
Shanghai-based Everest Medicines has announced the appointment of Kerry Blanchard as CEO. He will also join the company’s board of directors. Previously, he was operating partner of healthcare private equity firm CBC Group, CSO at Innovent Biologics, and senior vice president of Lilly China Drug Development and External Innovation.
Rodolphe Clerval has been appointed chief business officer of Paris-based gene therapy company Horama. Clerval has over 18 years of international experience in the pharma and biotech industry. Before joining Horama, he was cofounder and chief business officer at Enterome.
Troy Cox has been named chairman of Switzerland-based Sophia Genetics after serving on its board of directors for less than a year, taking over from Antoine Duchateau, who will remain on the company’s board. Cox was formerly CEO of the molecular testing company Foundation Medicine. Sophia also announced the appointment of Philippe Menu as chief medical officer. He joins from McKinsey & Company, where he co-led the McKinsey Cancer Center consultancy.
Markus Enzelberger has been named entrepreneur-in-residence of Ridgeline Therapeutics. He was formerly CSO at MorphoSys.
Douglas Fambrough has been appointed to the board of directors of TScan Therapeutics. Fambrough is a founder, president and CEO of Dicerna Pharmaceuticals.
Precision BioSciences has appointed Geno Germano, president and CEO of Elucida Oncology, to the company’s board of directors. Germano is a 30-year veteran of the pharma and life sciences industry who previously served as president of Intrexon and held multiple senior roles at Pfizer, Wyeth and Johnson & Johnson.
Spark Therapeutics’ cofounder, president and head of R&D Katherine High has resigned after seven years of leadership. Her departure comes two months after Roche acquired Spark for $4.3 billion.
Netherlands-based Pharvaris has appointed Peng Lu to the newly created position of chief medical officer. Lu brings 15 years of protein therapeutics and small molecule drug development experience, including within genetic rare diseases. She previously served as vice president, global program lead for rare diseases at Takeda.
Enterprise Therapeutics has named David Morris chief medical officer. Morris joins Enterprise from the Novartis Venture Fund, where he was a managing director and where he will maintain an appointment as an operating partner. He previously held various leadership roles at Novartis, including development franchise head of respiratory, development franchise head of primary care, and global head of clinical operations, analytics and regions.
Michael Quigley has joined Gilead Sciences as senior vice president, research biology. He was most recently vice president and head of Bristol-Myers Squibb’s thematic research center for tumor microenvironment modulation and site head of its Redwood City, California location.
Verana Health has appointed Matthew Roe chief medical officer. Roe is a cardiologist and clinical researcher who has spent over two decades at the Duke University School of Medicine and the Duke Clinical Research Institute, where he focused on research initiatives leveraging real-world data and patient engagement.
Aerie Pharmaceuticals has announced the appointment of Michelle Senchyna as vice president, clinical development and medical affairs. She most recently served as executive director of ophthalmology at Allergan.
Halozyme Therapeutics has named Elaine D. Sun senior vice president and CFO, succeeding Laurie Stelzer, who resigned to pursue another opportunity. Sun brings over 20 years of experience in investment banking and the life science industry, most recently serving as CFO and chief strategy officer at SutroVax.
Adaptate Biotherapeutics has appointed Mihriban Tuna as CSO. She brings over 15 years of experience in biologics drug discovery and development, joining the company from F-star, where she was senior vice president of drug discovery. Previously, she held key scientific roles at Domantis and GlaxoSmithKline.
Relmada Therapeutics has named Thomas C. Wessel executive vice president and head of R&D. Wessel previously served as chief medical officer at Acorda Therapeutics, at Flex Pharma and more recently at Asceneuron.